IOVA Stock — Iovance Biotherapeutics Inc.: Cash, EV, Pipeline

Share price

$10.25

Market cap

$4,643.0M

Cash

$297.7M

Enterprise value

$4,345.3M

Balance sheet

Cash	$297.7M
Debt	$0.0M
Net cash	$297.7M
Enterprise value	$4,345.3M
Basic shares	453.0M shares
Fully diluted shares	486.6M shares
Fully diluted market cap	$4,988.1M
Cash per share	$0.66

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading IOVA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	IOV-4001	Phase 2	Unresectable Melanoma; Metastatic Melanoma; Stage III Non-small Cell Lung Cancer	—
Apr 12 - May 24	Lifileucel plus Pembrolizumab	Phase 3	Metastatic Melanoma; Unresectable Melanoma; Melanoma	—
Jun 12 - Jul 24	Lifileucel	Phase 2	Endometrial Cancer	—
Nov 10 - Dec 22	LN-145	Phase 2	Cutaneous Squamous Cell Carcinoma; Merkel Cell Carcinoma; Metastatic Cutaneous Squamous Cell Carcinoma	—
Jan 12 - Feb 23	LN-145	Phase 2	Metastatic Non Small Cell Lung Cancer	—
Jul 13 - Aug 24	IOV-3001	Phase 2	Unresectable Melanoma; Metastatic Melanoma; Ocular Melanoma	—
Jan 12 - Feb 23	Lifileucel	Phase 2	Melanoma (Skin Cancer); Unresectable Melanoma; Metastatic Melanoma	—
May 13 - Jun 24	Interleukin-2	Phase 1	Malignant Pleural Effusion; Malignant Mesothelioma; Pleural Effusion, Malignant	—
Oct 13 - Nov 24	Lifileucel	Phase 2	Sarcoma; Soft Tissue Sarcoma (STS); Advanced Soft Tissue Sarcoma	—
Apr 12 - May 24	IOV-5001	Phase 2	Advanced Solid Tumors; Non-Small Cell Lung Cancer; Triple Negative Breast Cancer (TNBC)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Amtagvi

Approved · Active Modality: TIL cell therapy

Aliases lifileucel

Indications

Previously treated advanced melanoma (Approved)
Frontline advanced melanoma (TILVANCE-301 confirmatory) (Phase 3)
Previously treated advanced NSCLC (IOV-LUN-202) (Stage not disclosed)
Previously treated advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma (Stage not disclosed)

Catalysts

— later 2026
— 2027
— 2026 or 2027

Status note First one-time individualized T-cell therapy for a solid tumor; approved US, Canada, Australia (TGA Jun 2026). UK MAA resubmitted Jul 2026 under expedited MHRA review. Additional registrational trials in frontline melanoma, NSCLC, and sarcoma ongoing.

Proleukin

Approved · Active Modality: IL-2 biologic

Aliases aldesleukin

Target IL-2 receptor

Indications

Metastatic renal cell carcinoma (Approved)
Metastatic melanoma (Approved)

Status note IL-2 product used in the Amtagvi treatment regimen and other applications; worldwide rights acquired 2023. Approved product with product revenue.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Lifileucel plus Pembrolizumab
Lead indication	Metastatic Melanoma
Lead phase	Phase 3
Active trials	9
Collaborator trials	11

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05727904	Phase 3	Recruiting	Sponsor	IOVA	—	Metastatic Melanoma; Unresectable Melanoma; Melanoma	—
NCT05361174	Phase 2	Recruiting	Sponsor	IOVA	—	Unresectable Melanoma; Metastatic Melanoma; Stage III Non-small Cell Lung Cancer	—
NCT06481592	Phase 2	Recruiting	Sponsor	IOVA	—	Endometrial Cancer	—
NCT04614103	Phase 2	Recruiting	Sponsor	IOVA	—	Metastatic Non Small Cell Lung Cancer	—
NCT06940739	Phase 2	Recruiting	Sponsor	IOVA	—	Unresectable Melanoma; Metastatic Melanoma; Ocular Melanoma	—
NCT07288203	Phase 2	Active, not recruiting	Sponsor	IOVA	—	Melanoma (Skin Cancer); Unresectable Melanoma; Metastatic Melanoma	—
NCT07741877	Phase 2	Not yet recruiting	Sponsor	IOVA	—	Sarcoma; Soft Tissue Sarcoma (STS); Advanced Soft Tissue Sarcoma	—
NCT07743723	Phase 2	Not yet recruiting	Sponsor	IOVA	—	Advanced Solid Tumors; Non-Small Cell Lung Cancer; Triple Negative Breast Cancer (TNBC)	—
NCT06566092	Phase 1	Active, not recruiting	Sponsor	IOVA	—	Soft Tissue Sarcoma; Primary Central Nervous System Carcinoma; Melanoma	—
NCT05639972	Phase 2	Recruiting	Collaborator	Christian Hinrichs	—	HPV-Associated Cervical Carcinoma; HPV-Related Carcinoma; HPV-Related Malignancy	—
NCT05686226	Phase 2	Recruiting	Collaborator	Christian Hinrichs	—	Cervical Cancer; Throat Cancer; Oropharynx Cancer	—
NCT03449108	Phase 2	Active, not recruiting	Collaborator	M.D. Anderson Cancer Center	—	Bone Sarcoma; Dedifferentiated Chondrosarcoma; Giant Cell Tumor of Bone	—

Sponsor-matched active trials from ClinicalTrials.gov (9 as sponsor, 11 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 20 active trials for Iovance Biotherapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	146,090	+146,090	0.03%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

IOVA — Iovance Biotherapeutics Inc.